Some studies have suggested that glaucoma may be associated with neurodegeneration and a higher risk of dementia.
Objective
To evaluate whether exposure to different categories of topical glaucoma medications is associated with differential dementia risks in people with glaucoma.
Methods
We used data from Adult Changes in Thought, a population-based, prospective cohort study that follows cognitively normal older adults from Kaiser Permanente Washington (KPWA) until Alzheimer's disease (AD) and related dementia development. We included participants with a diagnosis of glaucoma, KPWA pharmacy records of filling topical glaucoma medication (alpha-adrenergic agonists [AAA], beta-adrenergic antagonists, miotics, carbonic anhydrase inhibitors [CAI], and prostaglandins) and at least 10 years of pharmacy records. Eight-year sliding windows were derived for each medication class by computing days on each medication starting 10 years earlier and excluding the most recent 2 years. Cox regression used all 5 classes of medication simultaneously to predict AD and all-cause dementia.
Results
We included 521 participants (mean age 78 [range 65–96], 62% female) with APOE genotype data. Beta-adrenergic antagonists were the most frequently prescribed (n = 431) followed by prostaglandins (351), AAA (239), CAI (162), and miotics (142). Adjusting for time-varying exposure to other glaucoma medications, APOE, demographics, and smoking, each year of use of alpha-adrenergic agonists in an 8-year window was associated with a higher risk of developing dementia (HR = 1.33, 95% CI = 1.03–1.72).
Conclusions
Among older adults with treated glaucoma, exposure to alpha-adrenergic agonists appears to be associated with risk for developing all-cause dementia.
Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 280–292.
2.
GauthierSWebsterCServaesS, et al.World Alzheimer Report 2022. Life after diagnosis: Navigating treatment, care and support. London, UK: Alzheimer’s Disease International, 2022.
3.
CouplandCACHillTDeningT, et al.Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med2019; 179: 1084–1093.
4.
OmuraJDMcGuireLCPatelR, et al.Modifiable risk factors for Alzheimer disease and related dementias among adults aged ≥45 years - United States, 2019. MMWR Morb Mortal Wkly Rep2022; 71: 680–685.
5.
Aiello BowlesEJCranePKWalkerRL, et al.Cognitive resilience to Alzheimer’s disease pathology in the human brain. J Alzheimers Dis2019; 68: 1071–1083.
6.
GatzMReynoldsCAFratiglioniL, et al.Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry2006; 63: 168–174.
7.
DourlenPKilincDMalmancheN, et al.The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis?Acta Neuropathol2019; 138: 221–236.
8.
PaulsenAJSchubertCRPintoAA, et al.Associations of sensory and motor function with blood-based biomarkers of neurodegeneration and Alzheimer’s disease in midlife. Neurobiol Aging2022; 120: 177–188.
9.
LivingstonGSommerladAOrgetaV, et al.Dementia prevention, intervention, and care. Lancet2017; 390: 2673–2734.
10.
HwangPHLongstrethWTJrThielkeSM, et al.Longitudinal changes in hearing and visual impairments and risk of dementia in older adults in the United States. JAMA Netw Open2022; 5: e2210734.
11.
EhrlichJRGoldsteinJSwenorBK, et al.Addition of vision impairment to a life-course model of potentially modifiable dementia risk factors in the US. JAMA Neurol2022; 79: 623–626.
12.
LeeCSLarsonEBGibbonsLE, et al.Associations between recent and established ophthalmic conditions and risk of Alzheimer’s disease. Alzheimers Dement2019; 15: 34–41.
13.
ShangXZhuZWangW, et al.The association between vision impairment and incidence of dementia and cognitive impairment: a systematic review and meta-analysis. Ophthalmology2021; 128: 1135–1149.
14.
SharifNA. Degeneration of retina-brain components and connections in glaucoma: disease causation and treatment options for eyesight preservation. Curr Res Neurobiol2022; 3: 100037.
15.
WardMEPetersenRC. Glaucoma and dementia: more than meets the eye?Ann Neurol2013; 74: 155–157.
16.
MancinoRMartucciACesareoM, et al.Glaucoma and Alzheimer disease: one age-related neurodegenerative disease of the brain. Curr Neuropharmacol2018; 16: 971–977.
17.
LiuYHTianT. Hypothesis of optineurin as a new common risk factor in normal-tension glaucoma and Alzheimer’s disease. Med Hypotheses2011; 77: 591–592.
18.
ChoiYK. An altered neurovascular system in aging-related eye diseases. Int J Mol Sci2022; 23: 14104.
19.
JainSArefAA. Senile dementia and glaucoma: evidence for a common link. J Ophthalmic Vis Res2015; 10: 178–183.
20.
TangMYBlazesMSLeeCS. Imaging amyloid and tau in the retina: current research and future directions. J Neuroophthalmol2023; 43: 168–179.
21.
LeeSJiangKMcIlmoyleB, et al.Amyloid beta immunoreactivity in the retinal ganglion cell layer of the Alzheimer’s eye. Front Neurosci2020; 14: 758.
22.
den HaanJMorremaTHJVerbraakFD, et al.Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas. Acta Neuropathol Commun2018; 6: 147.
23.
NizariSGuoLDavisBM, et al.Non-amyloidogenic effects of α2 adrenergic agonists: implications for brimonidine-mediated neuroprotection. Cell Death Dis2016; 7: e2514.
ThamYCLiXWongTY, et al.Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology2014; 121: 2081–2090.
26.
LarsonEBWangLBowenJD, et al.Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med2006; 144: 73–81.
27.
KukullWAHigdonRBowenJD, et al.Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol2002; 59: 1737–1746.
28.
WangLvan BelleGKukullWB,et al.Predictors of functional change: a longitudinal study of nondemented people aged 65 and older. J Am Geriatr Soc2002; 50: 1525–1534.
29.
LeeCSLeeMLGibbonsLE, et al.Associations between retinal artery/vein occlusions and risk of vascular dementia. J Alzheimers Dis2021; 81: 245–253.
30.
CranePKGibbonsLEMcCurrySM, et al.Importance of home study visit capacity in dementia studies. Alzheimers Dement2016; 12: 419–426.
31.
TengELHasegawaKHommaA, et al.The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr1994; 6: 45–58; discussion 62.
32.
CranePKTrittschuhEMukherjeeS, et al.Incidence of cognitively defined late-onset Alzheimer’s dementia subgroups from a prospective cohort study. Alzheimers Dement2017; 13: 1307–1316.
33.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Publishing, Inc., 1994.
34.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 263–269.
35.
VermuntLSikkesSAMvan den HoutA, et al.Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement2019; 15: 888–898.
36.
BelloyMENapolioniVGreiciusMD. A quarter century of APOE and Alzheimer’s disease: progress to date and the path forward. Neuron2019; 101: 820–838.
37.
LivingstonGHuntleyJLiuKY, et al.Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet2024; 404: 572–628.
38.
ZhongGWangYZhangY, et al.Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers. PLoS One2015; 10: e0118333.
39.
TaiXYVeldsmanMLyallDM, et al.Cardiometabolic multimorbidity, genetic risk, and dementia: a prospective cohort study. Lancet Healthy Longev2022; 3: e428–e436.
40.
KuźmaELouridaIMooreSF, et al.Stroke and dementia risk: a systematic review and meta-analysis. Alzheimers Dement2018; 14: 1416–1426.
41.
DoveAShangYXuW, et al.The impact of diabetes on cognitive impairment and its progression to dementia. Alzheimers Dement2021; 17: 1769–1778.
42.
SierraC. Hypertension and the risk of dementia. Front Cardiovasc Med2020; 7: 5.
43.
MathurMBDingPRiddellCA, et al.Web site and R package for computing E-values. Epidemiology2018; 29: e45–e47.
44.
VanderWeeleTJDingP. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med2017; 167: 268–274.
45.
SuCWLinCCKaoCH, et al.Association between glaucoma and the risk of dementia. Medicine2016; 95: e2833.
46.
ChenYYLaiYJYenYF, et al.Association between normal tension glaucoma and the risk of Alzheimer’s disease: a nationwide population-based cohort study in Taiwan. BMJ Open2018; 8: e022987.
47.
KeenanTDLGoldacreRGoldacreMJ. Associations between primary open angle glaucoma, Alzheimer’s disease and vascular dementia: record linkage study. Br J Ophthalmol2015; 99: 524–527.
48.
DongCJGuoYAgeyP, et al.Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci2008; 49: 4515–4522.
LiuJChangLSongY, et al.The role of NMDA receptors in Alzheimer’s disease. Front Neurosci2019; 13: 43.
51.
KarczewskiPHempelPKunzeR, et al.Agonistic autoantibodies to the α(1)-adrenergic receptor and the β(2) -adrenergic receptor in Alzheimer’s and vascular dementia. Scand J Immunol2012; 75: 524–530.
52.
KarczewskiPHempelPBimmlerM. Role of alpha1-adrenergic receptor antibodies in Alzheimer’s disease. Front Biosci2018; 23: 2082–2089.
53.
SlaterCWangQ. Alzheimer’s disease: an evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies. Clin Transl Med2021; 11: e397.
54.
MichelessiMLindsleyKYuT, et al.Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysis. Cochrane Database Syst Rev2014; 2014: CD011366.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
